PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $30M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | MRL Ventur... | mrlv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | Series A | $30M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 09.09.2021 | Roche to buy up diagnostics partner TIB Molbiol; PAQ t... | Roche is buying its longtime partner biotech TIB Molbiol Group, the Swiss drugmaker announce... | endpts.com... |
| 15.07.2021 | PAQ Therapeutics emerges with $30M series A for autophagy-ba... | PAQ Therapeutics hopes to break into the emerging field of autophagy, which is essentially the cell'... | fiercebiot... |
| - | PAQ Therapeutics scores $30M to unleash “Pac-Man” drugs on n... | Few biotech executives explain their experimental therapies by comparing them to video games. Nan Ji... | medcitynew... |